XML 74 R52.htm IDEA: XBRL DOCUMENT v3.19.1
Intangible assets (Details) - USD ($)
12 Months Ended
Aug. 28, 2014
Jun. 15, 2009
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Intangible assets          
Intangible assets, gross     $ 25,814,000 $ 25,809,000  
Accumulated amortization     (11,198,000) (9,461,000)  
Intangible assets, net     14,616,000 16,348,000  
Payment made to acquire asset     5,000 361,000 $ 500,000
Amortization expense     1,737,000 1,660,000 1,662,000
Aggregate amortization of intangible assets for each of the next five years and thereafter          
2019     1,737,000    
2020     1,737,000    
2021     1,737,000    
2022     1,737,000    
2023     1,642,000    
Thereafter     5,205,000    
Finite lived intangible assets, net     13,795,000    
Proprietary modified-release drug delivery technology          
Intangible assets          
Intangible assets, gross     15,600,000 15,600,000  
Amount of finite-lived intangibles   $ 15,600,000      
Useful life   20 years      
Tussionex ANDA          
Intangible assets          
Intangible assets, gross     4,829,000 4,829,000  
Payment made to acquire asset $ 4,200,000        
Legal fees 90,000        
Earnout fair value 589,000        
Tussionex ANDA | Other income (expense)          
Intangible assets          
Increase (decrease) in fair value of earnout liability     (133,000) (62,000) $ 18,000
CPI Profit Sharing          
Intangible assets          
Intangible assets, gross     2,043,000 2,043,000  
Payment made to acquire asset 2,000,000        
Legal fees $ 43,000        
Patents          
Intangible assets          
Intangible assets, gross     2,307,000 2,302,000  
Other          
Intangible assets          
Intangible assets, gross     $ 1,035,000 $ 1,035,000  
Tussionex ANDA and CPI profit sharing          
Intangible assets          
Useful life 10 years